Cargando…

ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma

SIMPLE SUMMARY: It is known that 9–15% of esophageal adenocarcinoma (EAC) tumors have ARID1A mutations. Studies have shown that ARID1A mutations play a role in the tumor immune phenotype. We aimed to investigate the immunomodulating effects of ARID1A deficiency in EAC. Our study implicates that ARID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Le, Zheng, Yueyuan, Chien, Wenwen, Ziman, Benjamin, Billet, Sandrine, Koeffler, H. Phillip, Lin, De-Chen, Bhowmick, Neil A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670331/ https://www.ncbi.nlm.nih.gov/pubmed/38001638 http://dx.doi.org/10.3390/cancers15225377

Ejemplares similares

Comprehensive analyses of partially methylated domains and differentially methylated regions in esophageal cancer reveal both cell-type- and cancer-specific epigenetic regulation
por: Zheng, Yueyuan, et al.
Publicado: (2023)

Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
por: Chien, Wenwen, et al.
Publicado: (2023)

Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer
por: Thiruvalluvan, Manish, et al.
Publicado: (2022)

Targeting HSPA1A in ARID2-deficient lung adenocarcinoma
por: Wang, Xue, et al.
Publicado: (2021)

Targeting genetic lesions in esophageal cancer
por: Lin, De-Chen, et al.
Publicado: (2014)

Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective
por: Lebedev, Timofey, et al.
Publicado: (2023)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice
por: Han, Lin, et al.
Publicado: (2019)

Dissecting the role of SWI/SNF component ARID1B in steady-state hematopoiesis
por: Madan, Vikas, et al.
Publicado: (2023)

Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma
por: Zhang, Zhenkun, et al.
Publicado: (2023)

Immune determinants of Barrett’s progression to esophageal adenocarcinoma
por: Lagisetty, Kiran H., et al.
Publicado: (2021)

Fatty Acid Signaling Impacts Prostate Cancer Lineage Plasticity in an Autocrine and Paracrine Manner
por: Zhang, Le, et al.
Publicado: (2022)

Mutational profiling of a MonoMAC syndrome family with GATA2 deficiency
por: Ding, Ling-Wen, et al.
Publicado: (2016)

Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
por: Salem, Ahmed F., et al.
Publicado: (2020)

Bone marrow mesenchymal stem cells interact with head and neck squamous cell carcinoma cells to promote cancer progression and drug resistance
por: Liu, Chuanxia, et al.
Publicado: (2020)

Publisher Correction: A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb target genes
por: Zheng, Yueyuan, et al.
Publicado: (2021)

A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb target genes
por: Zheng, Yueyuan, et al.
Publicado: (2021)

ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production
por: Sun, Dantong, et al.
Publicado: (2022)

Identification of prognostic genes and tumor-infiltrating immune cells in the tumor microenvironment of esophageal squamous cell carcinoma and esophageal adenocarcinoma
por: Huai, Qilin, et al.
Publicado: (2021)

The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma
por: Shaib, Walid L., et al.
Publicado: (2016)

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas
por: Soeratram, Tanya TD, et al.
Publicado: (2021)

Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival
por: Karstens, Karl-Frederick, et al.
Publicado: (2020)

Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Arbore, Giuseppina, et al.
Publicado: (2023)

Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model
por: Zaidi, Ali H., et al.
Publicado: (2021)

Tumor immune microenvironment in therapy‐naive esophageal adenocarcinoma could predict the nodal status
por: Kotsafti, Andromachi, et al.
Publicado: (2022)

Targeting the Metabolic Vulnerability of ARID1A-Deficient Hepatocellular Carcinoma
por: Chan, For-Fan, et al.
Publicado: (2022)

Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma
por: Zhang, Li, et al.
Publicado: (2018)

ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer
por: Moreno, Thaidy, et al.
Publicado: (2021)

Gingival fibroblasts resist apoptosis in response to oxidative stress in a model of periodontal diseases
por: Cheng, R, et al.
Publicado: (2015)

Chemoprevention of esophageal adenocarcinoma
por: Snider, Erik J, et al.
Publicado: (2020)

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021)

Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells
por: Cheng, Ran, et al.
Publicado: (2019)

Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer
por: Wu, Ray-Chang, et al.
Publicado: (2019)

Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma
por: Babar, Laila, et al.
Publicado: (2019)

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response
por: Ling, Chen, et al.
Publicado: (2022)

5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma
por: Ebelt, Nancy D., et al.
Publicado: (2020)

Significant Impacts of Increasing Aridity on the Arid Soil Microbiome
por: Neilson, Julia W., et al.
Publicado: (2017)

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
por: Takahashi, Kazuaki, et al.
Publicado: (2021)

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation
por: Zhao, Xue-Song, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j5c86igdmuu2mejs8hnf09jfvl